Loading...
CRXT CLARUS THERAPEUTICS HLDGS INC
Loading...
News
BRIEF-Clarus Therapeutics Announces Two Notices Of Allowance For Patent Claims Covering Jatenzo (Testosterone Undecanoate)
Oct 26 (Reuters) - Clarus Therapeutics Holdings IncCRXT.O :* CLARUS THERAPEUTICS ANNOUNCES TWO NOTICES OF ALLOWANCE FOR PATENT CLAIMS COVERING JATENZO (TESTOSTERONE UNDECANOATE)Source text for Eikon:
Top upgrades and downgrades on 10/6
New analysts' ratings released on Wednesday.
Clarus Therapeutics Hldgs Initiated at Buy by Needham
DJ Clarus Therapeutics Hldgs Initiated at Buy by Needham Ratings actions from Benzinga: https://www.benzinga.com/stock/CRXT/ratings (END) Dow Jones Newswires October 06, 2021 06:11 ET (10:11
BRIEF-Clarus Therapeutics Offers 19.82 Mln Common Shares By Selling Securityholders
Sept 30 (Reuters) - Clarus Therapeutics Holdings IncCRXT.O :* CLARUS THERAPEUTICS HOLDINGS INC FILES FOR OFFER AND SALE OF UP TO 19.82 MILLION SHARES OF COMMON STOCK BY THE SELLING SECURITYHOLDERS - S
Clarus Therapeutics Hldgs Initiated at Buy by Maxim Group
DJ Clarus Therapeutics Hldgs Initiated at Buy by Maxim Group Ratings actions from Benzinga: https://www.benzinga.com/stock/CRXT/ratings (END) Dow Jones Newswires September 29, 2021 09:32 ET
Clarus Therapeutics initiated at buy with $13 price target at Maxim
MW Clarus Therapeutics initiated at buy with $13 price target at Maxim (END) Dow Jones Newswires September 29, 2021 08:00 ET (12:00 GMT) Copyright (c) 2021 Dow Jones & Company, Inc.
13D Shows H.I.G.-GPII, Inc. Discloses 26.2% Active Stake In Clarus Therapeutics
13D Shows H.I.G.-GPII, Inc. Discloses 26.2% Active Stake In Clarus Therapeutics
Top upgrades and downgrades on 9/20
New analysts' ratings released on Monday.
Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12
Oppenheimer analyst Leland Gershell initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Outperform rating and announces Price Target of $12.
Clarus Therapeutics started at outperform with $12 stock price target at Oppenheimer
MW Clarus Therapeutics started at outperform with $12 stock price target at Oppenheimer (END) Dow Jones Newswires September 20, 2021 07:37 ET (11:37 GMT) Copyright (c) 2021 Dow Jones & Co